186 related articles for article (PubMed ID: 24711267)
1. Patterns of recurrence after trimodality therapy for esophageal cancer.
Dorth JA; Pura JA; Palta M; Willett CG; Uronis HE; D'Amico TA; Czito BG
Cancer; 2014 Jul; 120(14):2099-105. PubMed ID: 24711267
[TBL] [Abstract][Full Text] [Related]
2. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
[TBL] [Abstract][Full Text] [Related]
4. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
5. Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy.
Wood MD; Zaki BI; Gordon SR; Sutton JE; Lisovsky M; Gui J; Bubis JA; Dragnev KH; Rigas JR
J Thorac Oncol; 2013 Apr; 8(4):487-94. PubMed ID: 23370365
[TBL] [Abstract][Full Text] [Related]
6. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
[TBL] [Abstract][Full Text] [Related]
7. [Esophageal cancer: outcome according to therapeutic strategy].
Rousseau D; Capitain O; Denis F; Girault S; Poirier AL; Paumier A; Cellier P; Hamy A; Mahé MA; Mesgouez-Nebout N
Cancer Radiother; 2013 Feb; 17(1):10-20. PubMed ID: 23270680
[TBL] [Abstract][Full Text] [Related]
8. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer.
Hayashi Y; Xiao L; Suzuki A; Blum MA; Sabloff B; Taketa T; Maru DM; Welsh J; Lin SH; Weston B; Lee JH; Bhutani MS; Hofstetter WL; Swisher SG; Ajani JA
Eur J Cancer; 2012 Dec; 48(18):3396-404. PubMed ID: 22853875
[TBL] [Abstract][Full Text] [Related]
9. Isolated local recurrence or solitary solid organ metastasis after esophagectomy for cancer is not the end of the road.
Depypere L; Lerut T; Moons J; Coosemans W; Decker G; Van Veer H; De Leyn P; Nafteux P
Dis Esophagus; 2017 Jan; 30(1):1-8. PubMed ID: 27704661
[TBL] [Abstract][Full Text] [Related]
10. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
[TBL] [Abstract][Full Text] [Related]
11. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.
Sepesi B; Schmidt HE; Lada M; Correa AM; Walsh GL; Mehran RJ; Rice DC; Roth JA; Vaporciyan AA; Ajani JA; Watson TJ; Swisher SG; Low DE; Hofstetter WL
Ann Thorac Surg; 2016 Mar; 101(3):1075-80; Discussion 1080-1. PubMed ID: 26680311
[TBL] [Abstract][Full Text] [Related]
12. Long-term Treatment Outcomes for Locally Advanced Esophageal Cancer: A Single-Institution Experience.
Sio TT; Wilson ZC; Stauder MC; Bhatia S; Martenson JA; Quevedo JF; Schomas DA; Miller RC
Am J Clin Oncol; 2016 Oct; 39(5):448-52. PubMed ID: 24879469
[TBL] [Abstract][Full Text] [Related]
13. Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer.
Motoori M; Yano M; Ishihara R; Yamamoto S; Kawaguchi Y; Tanaka K; Kishi K; Miyashiro I; Fujiwara Y; Shingai T; Noura S; Ohue M; Ohigashi H; Nakamura S; Ishikawa O
Ann Surg Oncol; 2012 Jul; 19(7):2135-41. PubMed ID: 22302264
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?
Monjazeb AM; Riedlinger G; Aklilu M; Geisinger KR; Mishra G; Isom S; Clark P; Levine EA; Blackstock AW
J Clin Oncol; 2010 Nov; 28(31):4714-21. PubMed ID: 20876421
[TBL] [Abstract][Full Text] [Related]
15. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma.
Hashimoto J; Kato K; Ito Y; Kojima T; Akimoto T; Daiko H; Hamamoto Y; Matsushita H; Katano S; Hara H; Tanaka Y; Saito Y; Nagashima K; Igaki H
Int J Clin Oncol; 2019 Jan; 24(1):60-67. PubMed ID: 30109544
[TBL] [Abstract][Full Text] [Related]
16. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
[TBL] [Abstract][Full Text] [Related]
17. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma.
Kumabe A; Fukada J; Kota R; Koike N; Shiraishi Y; Seki S; Yoshida K; Kitagawa Y; Shigematsu N
Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29228166
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of trimodality CROSS regimen in older adults with locally advanced esophageal cancer.
Cooper L; Dezube AR; De León LE; Kucukak S; Mazzola E; Dumontier C; Mamon H; Enzinger P; Jaklitsch MT; Frain LN; Wee JO
Eur J Surg Oncol; 2021 Oct; 47(10):2667-2674. PubMed ID: 33895020
[TBL] [Abstract][Full Text] [Related]
20. [Patterns of recurrence in patients with stage pT3N0M0 thoracic esophageal squamous cell carcinoma after two-field esophagectomy].
Wang Y; Wang L; Yang Q; Li J; He M; Yao J; Qi Z; Li B; Qiao X
Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):48-54. PubMed ID: 26796807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
